Literature DB >> 18334915

Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients.

Séverine Crettol1, Jean-Pierre Venetz, Massimiliano Fontana, John-David Aubert, Nicolas Ansermot, Marc Fathi, Manuel Pascual, Chin B Eap.   

Abstract

OBJECTIVE: The expression on lymphocytes of P-glycoprotein, an efflux transporter encoded by the ABCB1 gene, might influence cyclosporine intracellular concentration.
METHODS: ABCB1 genotypes, cyclosporine intracellular and blood concentrations were determined in 64 stable renal, liver or lung transplant recipients.
RESULTS: Cyclosporine intracellular concentration correlated moderately with blood concentration (r=0.30, P<0.00005). The ABCB1 1199A carriers presented a 1.8-fold decreased cyclosporine intracellular concentration (P=0.04), whereas the 3435T carriers presented a 1.7-fold increase (P=0.02) as well as a 1.2-fold increased blood concentration (P=0.04). In contrast, ABCB1 61A>G, 1236C>T and 2677G>T polymorphisms did not influence cyclosporine intracellular and blood concentrations.
CONCLUSION: This is the first report demonstrating that ABCB1 polymorphisms influence cyclosporine intracellular concentration. Interestingly, its influence on intracellular concentration is significantly higher than on blood concentration (P<0.002). This may therefore modulate cyclosporine immunosuppressive activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334915     DOI: 10.1097/FPC.0b013e3282f7046f

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  25 in total

1.  Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.

Authors:  J-B Woillard; J-P Rerolle; N Picard; A Rousseau; A Guillaudeau; E Munteanu; M Essig; M Drouet; Y Le Meur; P Marquet
Journal:  Clin Pharmacol Ther       Date:  2010-05-26       Impact factor: 6.875

Review 2.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 3.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 4.  The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.

Authors:  Nicolas Picard; Pierre Marquet
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-03-25       Impact factor: 4.481

Review 5.  Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.

Authors:  Teun van Gelder; Ron H van Schaik; Dennis A Hesselink
Journal:  Nat Rev Nephrol       Date:  2014-09-23       Impact factor: 28.314

Review 6.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

Review 7.  Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS.

Authors:  Mwlod Ghareeb; Fatemeh Akhlaghi
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

8.  Donor ABCB1 variant associates with increased risk for kidney allograft failure.

Authors:  Jason Moore; Amy Jayne McKnight; Bernd Döhler; Matthew J Simmonds; Aisling E Courtney; Oliver J Brand; David Briggs; Simon Ball; Paul Cockwell; Christopher C Patterson; Alexander P Maxwell; Stephen C L Gough; Gerhard Opelz; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2012-10-11       Impact factor: 10.121

9.  ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation.

Authors:  Jun-Jun Jia; Bin-Yi Lin; Jiang-Juan He; Lei Geng; Dhruba Kadel; Li Wang; Dong-Dong Yu; Tian Shen; Zhe Yang; Yu-Fu Ye; Lin Zhou; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

10.  The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.

Authors:  Finn Gustafsson; David Barth; Diego H Delgado; Meerna Nsouli; Jill Sheedy; Heather J Ross
Journal:  Eur J Clin Pharmacol       Date:  2009-05-21       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.